Jacques MARESCAUX, Professor of Digestive Surgery, President and founder of IRCAD This new device gives great hope to many diabetic patients. 'We are proud of this entry into the clinical phase of the ExOlin В® device, the result of close collaboration between Defymed and IRCAD since 2011, after many years of joint research.В Defymed has been able to improve and adapt this revolutionary device by drawing on the surgical expertise of the IRCAD.В The entire IRCAD team was enthusiastic about the announcement of the validation of this medical device for insulin delivery in humans. Nathalie JEANDIDIER, PU-PH - Head of the Department of Endocrinology, Diabetes and Nutrition Such a device will enable physiological, effective insulin administration, limiting the acute and chronic complications of diabetes and improving the patient's quality of life and autonomy of management'. 'The HUS diabetes and endocrinology team is very pleased with the authorization to enter the clinical phase of the ExOlin В® system this is the result of many years of collaboration with Defymed and the IRCAD on innovative projects in diabetes centered on insulin infusion allowing a first hepatic passage.

Nathalie Jeandidier, Head of the Endocrinology, Diabetes and Nutrition Department of the HUS. The patients will be included and monitored by Prof. To conduct this first-in-human safety and performance investigation, the number of patients implanted was set at 8, based on staggered recruitment. ExOlin В® brings the hope for a more physiologic treatment for diabetic patients, that aims to their unmet medical needs'Дr SГ©verine SIGRIST, President of DefymedДЁ patients implanted according to a surgical protocol developed in collaboration with the University Hospital of Strasbourg (HUS) and the IRCAD a centre of excellence for laparoscopic surgery training. It is also thanks to the expertise and support from French and European stakeholders that we are proud to reach a key Milestone in Defymed's mission at the service of diabetic patients. This is just the first step, but it has taken many years of development to ensure the safety and efficacy of the ExOlin В® device for the benefit of the patient. 'The fact that the French competent authority has granted the authorisation to enter the clinical phase is the result of many years of research by the Defymed teams to improve the quality of life of diabetic patients. This first phase of clinical entry, estimated to last 18 months and to start in the first quarter of 2022, aims to validate the benefit of physiological insulin delivery for diabetic patients with ExOlin В® and to evaluate the safety and tolerability of this new device.

Israel type 1 diabetes pilot